Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug News Perspect. 2009 Jan-Feb;22(1):61-4. doi: 10.1358/dnp.2009.22.1.1303820.

Asparagine synthetase: a new potential biomarker in ovarian cancer.

Author information

  • 1Genomics & Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer Research (CCR), National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. lorenzip@mail.nih.gov

Abstract

L-Asparaginase (L-ASP) is an enzyme drug that has been an asset to leukemia treatment regimens for four decades. Variability in its clinical efficacy, however, has prompted the search for biomarkers capable of distinguishing responders from non-responders. In that regard, the NCI-60 cell line panel has served as a biomarker discovery platform and has led to the identification of a correlation between L-ASP efficacy and asparagine synthetase (ASNS) expression in cultured cells. The presence of that correlation in the ovarian subpanel of the NCI-60 has made a case for repositioning L-ASP to ovarian cancer. This review presents an overview of the biomarker development process, summarizes the efforts that have been invested thus far in developing ASNS as a biomarker for ovarian cancer treatment, highlights the role of RNAi and the limitations of the NCI-60 in that process, and addresses important considerations for next steps in the development of ASNS as a predictive biomarker.

Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk